• Romosozumab May Not Increase Cardiovascular Risk After All

    12 days ago - By Medscape

    Alarm bells went off at the FDA because during year 1 of the ARCH trial, the incidence of adjudicated major adverse cardiovascular events was 2.5% in the romosozumab arm, compared with 1.9% with alendronate.
    Medscape Medical News
    Read more ...